Publication | Closed Access

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

MedicinePathologyPhase Ii StudyWeekly PaclitaxelFirst-line TreatmentHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation Oncology